Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ingersoll Rand (IR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ingersoll Rand — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $385.16 (market cap $10.27B), while Ingersoll Rand trades at $76.94 (market cap $29.27B). The key difference: Ingersoll Rand is far larger — about 2.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Ingersoll Rand pays a 0.11% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Bio-Rad Laboratories, Inc. Class A Common Stock for 60 Days and Ingersoll Rand for 12 Days on average.
| BIO | IR | |
|---|---|---|
Market Cap | $10.27B | $29.27B |
Volume | 251,320 | 2,799,048 |
Sector | Health | Industrials |
52-Week High | $390.34 | $98.76 |
52-Week Low | $241.71 | $68.54 |
Typical Hold Time | 60 Days | 12 Days |
Enterprise Value | $10.02B | $32.93B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $386.61, up 1.48% with a bullish technical signal and strong institutional support. The company shows improving fundamentals with $760M net income in 2025, reversing previous losses, though recent earnings misses and a high P/E of 46.91 warrant caution. Positive news includes expansion in identity security and digital PCR technology growth.
Outlook remains cautiously optimistic with 57% analyst buy ratings and a $350 consensus target. Key opportunities include margin expansion and international growth, while risks involve valuation premium, China exposure, and geopolitical factors. The stock's momentum depends on executing operational improvements amid competitive pressures.
Ingersoll Rand (IR) trades at $75.53, up 1.36% with a bearish technical outlook despite recent earnings beats. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and improving profitability margins. Recent acquisition of Lone Star Blower expands industrial capabilities while analysts maintain a buy consensus with $92.40 price target.
IR presents a mixed investment case with strong operational performance offset by elevated valuation concerns. The stock offers upside to analyst targets but faces margin pressure risks and technical headwinds. Key catalysts include Q3 earnings results and continued execution on growth initiatives across both industrial and precision technology segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →
